特立氟胺与富马酸二甲酯治疗多发性硬化的比较效果
本研究在法国多发性硬化观察队列中比较特立氟胺(TRF)与富马酸二甲酯(DMF)对复发缓解型多发性硬化(RRMS)的临床和MRI结局。纳入1770例患者(TRF 713例,DMF 1057例),采用倾向评分加权分析。2年后两组临床复发和残疾进展相似,但DMF组新发T2病灶比例更低(60.8% vs 72.2%),且因疗效不佳停药率更低。
要点
- TRF与DMF治疗2年后临床复发和残疾进展相似
- DMF组2年内新发T2病灶比例显著低于TRF组
- DMF因疗效不佳停药率低于TRF,但不良事件停药率更高
核心结论
- 治疗2年后,DMF与TRF在临床结局上效果相似,但DMF的MRI结局更优,因疗效不佳停药率更低。
研究设计与样本
- 基于法国多发性硬化观察队列的前瞻性研究,纳入1770例RRMS患者(TRF 713例,DMF 1057例),均具备基线脑MRI,采用意向性治疗分析,使用倾向评分逆概率加权和逻辑回归。
主要发现
- 调整混杂因素后,TRF与DMF组在1年和2年时的复发和残疾进展比例相似。
- 2年内至少一个新发T2病灶的患者比例DMF组为60.8%,TRF组为72.2%(OR 0.60,p < 0.001)。
- 因疗效不佳停药的患者比例DMF组为8.5%,TRF组为14.5%(OR 0.54,p < 0.001)。
- 2年内因不良事件停药的患者比例TRF组为16%,DMF组为21%(OR 1.39,p < 0.001)。
临床怎么用
- 对于RRMS患者,DMF和TRF在临床疗效上相似,但DMF在MRI病灶控制方面更优,因疗效不佳停药更少。
- 选择治疗时需权衡DMF的MRI优势与较高的不良事件停药风险。
局限性
- 本研究为观察性队列研究,证据等级为Class III,可能存在未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In this study, we compared the effectiveness of teriflunomide (TRF) and dimethyl fumarate (DMF) on both clinical and MRI outcomes in patients followed prospectively in the Observatoire Français de la Sclérose en Plaques. METHODS: A total of 1,770 patients with relapsing-remitting multiple sclerosis (RRMS) (713 on TRF and 1,057 on DMF) with an available baseline brain MRI were included in intention to treat. The 1- and 2-year postinitiation outcomes were relapses, increase of T2 lesions, increase in Expanded Disability Status Scale score, and reason for treatment discontinuation. Propensity scores (inverse probability weighting) and logistic regressions were estimated. RESULTS: The confounder-adjusted proportions of patients were similar in TRF- compared to DMF-treated patients for relapses and disability progression after 1 and 2 years. However, the adjusted proportion of patients with at least one new T2 lesion after 2 years was lower in DMF compared to TRF (60.8% vs 72.2%, odds ratio [OR] 0.60, p < 0.001). Analyses of reasons for treatment withdrawal showed that lack of effectiveness was reported for 8.5% of DMF-treated patients vs 14.5% of TRF-treated patients (OR 0.54, p < 0.001), while adverse events accounted for 16% of TRF-treated patients and 21% of DMF-treated patients after 2 years (OR 1.39, p < 0.001). CONCLUSIONS: After 2 years of treatment, we found similar effectiveness of DMF and TRF in terms of clinical outcomes, but with better MRI-based outcomes for DMF-treated patients, resulting in a lower rate of treatment discontinuation due to lack of effectiveness. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with RRMS, TRF and DMF have similar clinical effectiveness after 2 years of treatment.
引用
- Laplaud DA, Casey R, Barbin L, et al. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology. 2019. PMID: 31300547. doi:10.1212/WNL.0000000000007938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。